guest ::
| Home > Publications Database > Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. > print |
| Home > Publications Database > Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. > print |
| 001 | 139678 | ||
| 005 | 20240321220649.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.27199 |2 doi |
| 024 | 7 | _ | |a pmid:29094781 |2 pmid |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a altmetric:28321848 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-06000 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Lerche, Stefanie |0 P:(DE-2719)2812186 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. |
| 260 | _ | _ | |a New York, NY |c 2017 |b Wiley |
| 264 | _ | 1 | |3 online |2 Crossref |b Wiley |c 2017-11-02 |
| 264 | _ | 1 | |3 print |2 Crossref |b Wiley |c 2017-12-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1590492545_19706 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a A proportion of idiopathic Parkinson's disease patients (PDidiopathic ) with dementia show altered CSF profiles of amyloid β (Aβ) and Tau. PD patients with Glucocerebrosidase (GBA) mutations (PDGBA ) present with even more cognitive decline than seen in PDidiopathic .The objective of this study was to evaluate whether CSF profiles of Aβ and tau are associated with the prominent cognitive impairment in PDGBA .CSF levels of Aβ1-42 , t-Tau, p-Tau, and total alpha-synuclein were assessed in 479 participants (50 PDGBA , 308 PDidiopathic , 121 healthy controls).Older age was associated with cognitive impairment in PDGBA and PDidiopathic . Despite prominent cognitive impairment, PDGBA showed similar CSF levels of Aβ1-42 , t-Tau, and p-Tau as seen in healthy controls. In contrast, lower levels of Aβ1-42 and higher levels of t-Tau and p-Tau were associated with worse cognitive performance in PDidiopathic .The prominent cognitive impairment in PDGBA seems not primarily associated with Aβ and Tau profiles in CSF. © 2017 International Parkinson and Movement Disorder Society. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 1 |
| 542 | _ | _ | |i 2017-11-02 |2 Crossref |u http://doi.wiley.com/10.1002/tdm_license_1.1 |
| 542 | _ | _ | |i 2017-11-02 |2 Crossref |u http://onlinelibrary.wiley.com/termsAndConditions#vor |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Peptide Fragments |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-42) |2 NLM Chemicals |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Glucosylceramidase |0 EC 3.2.1.45 |2 NLM Chemicals |
| 650 | _ | 2 | |a Adolescent |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Cognition Disorders: etiology |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Glucosylceramidase: genetics |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Mutation: genetics |2 MeSH |
| 650 | _ | 2 | |a Neuropsychological Tests |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: complications |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Peptide Fragments: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Severity of Illness Index |2 MeSH |
| 650 | _ | 2 | |a Statistics, Nonparametric |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: cerebrospinal fluid |2 MeSH |
| 700 | 1 | _ | |a Schulte, Claudia |0 P:(DE-2719)9000366 |b 1 |u dzne |
| 700 | 1 | _ | |a Srulijes, Karin |0 P:(DE-2719)9000298 |b 2 |u dzne |
| 700 | 1 | _ | |a Pilotto, Andrea |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Rattay, Tim W |0 P:(DE-2719)2811827 |b 4 |u dzne |
| 700 | 1 | _ | |a Hauser, Ann-Kathrin |0 P:(DE-2719)2351249 |b 5 |u dzne |
| 700 | 1 | _ | |a Stransky, Elke |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Deuschle, Christian |0 P:(DE-2719)2812432 |b 7 |u dzne |
| 700 | 1 | _ | |a Csoti, Ilona |b 8 |
| 700 | 1 | _ | |a Lachmann, Ingolf |b 9 |
| 700 | 1 | _ | |a Zetterberg, Henrik |b 10 |
| 700 | 1 | _ | |a Liepelt-Scarfone, Inga |0 P:(DE-2719)2109499 |b 11 |u dzne |
| 700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 12 |u dzne |
| 700 | 1 | _ | |a Maetzler, Walter |0 P:(DE-2719)2810915 |b 13 |u dzne |
| 700 | 1 | _ | |a Berg, Daniela |0 P:(DE-2719)2000059 |b 14 |u dzne |
| 700 | 1 | _ | |a Brockmann, Kathrin |0 P:(DE-2719)2811916 |b 15 |e Last author |u dzne |
| 773 | 1 | 8 | |a 10.1002/mds.27199 |b : Wiley, 2017-11-02 |n 12 |p 1780-1783 |3 journal-article |2 Crossref |t Movement Disorders |v 32 |y 2017 |x 0885-3185 |
| 773 | _ | _ | |a 10.1002/mds.27199 |g Vol. 32, no. 12, p. 1780 - 1783 |0 PERI:(DE-600)2041249-6 |n 12 |q 32:12<1780 - 1783 |p 1780-1783 |t Movement disorders |v 32 |y 2017 |x 0885-3185 |
| 909 | C | O | |o oai:pub.dzne.de:139678 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2812186 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9000366 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)9000298 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2811827 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2351249 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2812432 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2109499 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2320009 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2810915 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2000059 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2811916 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |2 G:(DE-HGF)POF3-300 |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |2 G:(DE-HGF)POF3-300 |v Population Studies and Genetics |x 1 |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-11 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2021 |d 2022-11-11 |
| 920 | 1 | _ | |0 I:(DE-2719)6000018 |k Tübingen Pre 2020 |l Tübingen Pre 2020 |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000055 |k AG Berg |l Parkinson's Disease Genetics AG Berg |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser 1 |l Parkinson Genetics |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)5000024 |k AG Maetzler |l Functional Neurogeriatrics |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)6000018 |
| 980 | _ | _ | |a I:(DE-2719)5000055 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)5000024 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1212/WNL.0b013e3181f61311 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0b013e3181f61311 |
| 999 | C | 5 | |a 10.1007/s00401-016-1552-2 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00401-016-1552-2 |
| 999 | C | 5 | |a 10.1056/NEJMoa033277 |9 -- missing cx lookup -- |2 Crossref |o 10.1056/NEJMoa033277 |
| 999 | C | 5 | |a 10.1016/j.parkreldis.2015.10.008 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.parkreldis.2015.10.008 |
| 999 | C | 5 | |a 10.1056/NEJMoa0901281 |9 -- missing cx lookup -- |2 Crossref |o 10.1056/NEJMoa0901281 |
| 999 | C | 5 | |a 10.1212/WNL.0b013e318225ab77 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0b013e318225ab77 |
| 999 | C | 5 | |a 10.1093/brain/aws318 |9 -- missing cx lookup -- |2 Crossref |o 10.1093/brain/aws318 |
| 999 | C | 5 | |a 10.1002/mds.26071 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.26071 |
| 999 | C | 5 | |a 10.1002/mds.23991 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.23991 |
| 999 | C | 5 | |a 10.1007/s00702-014-1276-1 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00702-014-1276-1 |
| 999 | C | 5 | |a 10.1002/mds.10459 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.10459 |
| 999 | C | 5 | |a 10.1002/mds.22340 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.22340 |
| 999 | C | 5 | |a 10.1002/mds.20213 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.20213 |
| 999 | C | 5 | |a 10.1212/WNL.0b013e3181c34b47 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0b013e3181c34b47 |
| 999 | C | 5 | |a 10.1016/0022-3956(75)90026-6 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/0022-3956(75)90026-6 |
| 999 | C | 5 | |a 10.1002/mds.26062 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/mds.26062 |
| 999 | C | 5 | |a 10.1007/s00401-008-0344-8 |9 -- missing cx lookup -- |2 Crossref |o 10.1007/s00401-008-0344-8 |
| 999 | C | 5 | |a 10.1093/brain/awr031 |9 -- missing cx lookup -- |2 Crossref |o 10.1093/brain/awr031 |
| 999 | C | 5 | |a 10.1212/WNL.0000000000001098 |9 -- missing cx lookup -- |2 Crossref |o 10.1212/WNL.0000000000001098 |
| 999 | C | 5 | |a 10.1016/j.parkreldis.2014.12.027 |9 -- missing cx lookup -- |2 Crossref |o 10.1016/j.parkreldis.2014.12.027 |
| 999 | C | 5 | |a 10.1111/ane.12247 |9 -- missing cx lookup -- |2 Crossref |o 10.1111/ane.12247 |
| 999 | C | 5 | |a 10.1093/brain/awp044 |9 -- missing cx lookup -- |2 Crossref |o 10.1093/brain/awp044 |
| 999 | C | 5 | |a 10.1002/ana.20635 |9 -- missing cx lookup -- |2 Crossref |o 10.1002/ana.20635 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|